Zhejiang Medicine Co., Ltd. (SHA:600216)

Market Cap	15.41B +6.7%
Revenue (ttm)	8.96B -0.8%
Net Income	1.24B +27.2%
EPS	1.30 +26.0%
Shares Out	947.91M
PE Ratio	12.53
Forward PE	15.06
Dividend	0.37 (2.32%)
Ex-Dividend Date	Jul 21, 2025

Volume	16,568,672
Average Volume	43,542,829
Open	16.33
Previous Close	16.26
Day's Range	15.83 - 16.58
52-Week Range	11.60 - 18.58
Beta	0.65
RSI	49.05
Earnings Date	Apr 24, 2026

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin produc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 5,815
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2024, Zhejiang Medicine's revenue was 9.38 billion, an increase of 20.29% compared to the previous year's 7.79 billion. Earnings were 1.16 billion, an increase of 170.11%.